Methoxphenidine
Chemical compound
From Wikipedia, the free encyclopedia
Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug.[1][2] Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury.[3] Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form.[4] Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency.[1] Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine,[3][5] a structure–activity relationship shared by the arylcyclohexylamines.[6]
administrationOral, Rectal
- AU: S9 (Prohibited substance)
- BR: Class F2 (Prohibited psychotropics)
- CA: Schedule I
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
- Illegal in China and Sweden
| |
| Clinical data | |
|---|---|
| Routes of administration | Oral, Rectal |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H25NO |
| Molar mass | 295.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Side effects
Acute methoxphenidine intoxication has been reported to produce confusion, hypertension, and tachycardia that was responsive to treatment with intravenous lorazepam,[7][8] methoxphenidine has also been associated with three published fatalities[9] and one case of impaired driving.[10]
Psychotic episodes have also been reported, including a murder in June 2014.[11]
Legal status
As of October 2015 MXP is a controlled substance in China.[12]
MXP is also banned in Sweden.[13]
In Canada, MT-45 and its analogues were made Schedule I controlled substances, which includes DPD[clarification needed] in its structural group.[14] Possession without legal authority can result in maximum seven years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify explicitly DPD as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
In Australia, the Therapeutic Goods Administration decided to include methoxphenidine as a Prohibited substance (Schedule 9) within the Standard for the Uniform Scheduling of Medicines and Poisons alongside four other phenidine analogs on 1 October 2024.[15]